New Phase 3 trial: A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP — Jiangsu Hansoh Pharmaceutical Co., Ltd.

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-21 12:00 UTC

KINDCompany

DIRECTION■ Mixed

SOURCES1

ENTITIES0

STORY SIZESTANDALONE

FIRST SEEN2026-10-21 12:00 UTC

LAST UPDATE2026-10-21 12:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.

FULL DISPATCH

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.; Status: Not Yet Recruiting; Conditions: Chronic Myeloid Leukemia; Interventions: HS-10382, Imatinib, Dasatinib; Enrollment: 408 (estimated); First posted: 2026-10-21; NCT: NCT07885293

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

NO ENTITY LINKS AT DISPLAY CONFIDENCE YET.

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-21 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

←INFERENCEfilings generate company commentary
META filed 10-Q on 2026-10-222026-10-22 00:00 UTC

←INFERENCEfilings generate company commentary
TSLA filed 10-Q on 2026-10-222026-10-22 00:00 UTC

←INFERENCEfilings generate company commentary
LMT filed 8-K on 2026-10-222026-10-22 00:00 UTC

←INFERENCEfilings generate company commentary
WDC filed 8-K on 2026-10-222026-10-22 00:00 UTC

←INFERENCEfilings generate company commentary
LMT filed 10-Q on 2026-10-222026-10-22 00:00 UTC

←INFERENCEfilings generate company commentary
WDC filed 4 on 2026-10-222026-10-22 00:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.